IN2014CN01970A - - Google Patents

Download PDF

Info

Publication number
IN2014CN01970A
IN2014CN01970A IN1970CHN2014A IN2014CN01970A IN 2014CN01970 A IN2014CN01970 A IN 2014CN01970A IN 1970CHN2014 A IN1970CHN2014 A IN 1970CHN2014A IN 2014CN01970 A IN2014CN01970 A IN 2014CN01970A
Authority
IN
India
Prior art keywords
biomarkers
event
years
risk
methods
Prior art date
Application number
Inventor
Rosalynn Dianne Gill
Stephen Alaric Williams
Alex A E Stewart
Robert Mehler
Trudi Foreman
Britta Singer
Original Assignee
Somalogic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Somalogic Inc filed Critical Somalogic Inc
Publication of IN2014CN01970A publication Critical patent/IN2014CN01970A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Databases & Information Systems (AREA)
  • Data Mining & Analysis (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)

Abstract

Biomarkers methods devices reagents systems and kits for the evaluation of risk of a caradiovascular (CV) event within 5 years are disclosed. The biomarkers that can be used alone or in various combinations to evaluate risk of a CV event within 5 years. The methods are provided for evaluating risk of a CV event within 5 years in an individual where the methods include detecting in a biological sample from an individual at least one biomarker value the biomarker being selected from a group of biomarkers.
IN1970CHN2014 2011-09-30 2012-09-28 IN2014CN01970A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161541828P 2011-09-30 2011-09-30
PCT/US2012/058060 WO2013049674A1 (en) 2011-09-30 2012-09-28 Cardiovascular risk event prediction and uses thereof

Publications (1)

Publication Number Publication Date
IN2014CN01970A true IN2014CN01970A (en) 2015-05-29

Family

ID=47993164

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1970CHN2014 IN2014CN01970A (en) 2011-09-30 2012-09-28

Country Status (17)

Country Link
US (3) US20130085079A1 (en)
EP (1) EP2761289B1 (en)
JP (3) JP6652781B2 (en)
KR (2) KR102111624B1 (en)
CN (4) CN103959060B (en)
AU (1) AU2013202112B9 (en)
BR (2) BR112014007214B1 (en)
CA (2) CA3074279C (en)
ES (1) ES2777002T3 (en)
HK (1) HK1247666A1 (en)
IL (1) IL231387A (en)
IN (1) IN2014CN01970A (en)
MX (2) MX2014003153A (en)
RU (1) RU2651708C2 (en)
SG (3) SG10201607331WA (en)
WO (1) WO2013049674A1 (en)
ZA (1) ZA201401778B (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
JP6055966B2 (en) * 2010-06-07 2017-01-11 マイクロ‐シグネチャー リミテッド Detection method
CA2801110C (en) 2010-07-09 2021-10-05 Somalogic, Inc. Lung cancer biomarkers and uses thereof
CA2804857C (en) 2010-08-13 2021-07-06 Somalogic, Inc. Pancreatic cancer biomarkers and uses thereof
KR20140015455A (en) 2011-03-10 2014-02-06 소마로직, 인크. Aptamers for clostridium difficile diagnostics
SG10201607331WA (en) * 2011-09-30 2016-11-29 Somalogic Inc Cardiovascular risk event prediction and uses thereof
JP6198047B2 (en) * 2013-08-02 2017-09-20 国立大学法人岐阜大学 Coronary artery disease test kit
US9926566B2 (en) 2013-09-24 2018-03-27 Somalogic, Inc. Multiaptamer target detection
EP3517964B1 (en) * 2014-03-21 2022-04-13 Sanofi-Aventis Deutschland GmbH New markers for the assessment of the risk for development of a cardiovascular disorder
CA2949731A1 (en) * 2014-06-05 2015-12-10 Sanofi-Aventis Deutschland Gmbh New markers for the assessment of an increased risk for mortality
AU2014407088B2 (en) * 2014-09-26 2021-09-23 Somalogic Operating Co., Inc. Cardiovascular risk event prediction and uses thereof
WO2016123163A2 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
US20190017117A1 (en) * 2015-07-10 2019-01-17 West Virginia University Markers of stroke and stroke severity
RU2602451C1 (en) * 2015-08-28 2016-11-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого" Министерства здравоохранения Российской Федерации Diagnostic technique for genetic predisposition to ischemic stroke development in patients with atrial fibrillation
MX2018009170A (en) * 2016-02-08 2018-11-19 Somalogic Inc Nonalcoholic fatty liver disease (nafld) and nonalcoholic steatohepatitis (nash) biomarkers and uses thereof.
EP3426826A4 (en) * 2016-03-09 2019-09-04 Molecular Stethoscope, Inc. Methods and systems for detecting tissue conditions
WO2017174696A1 (en) * 2016-04-06 2017-10-12 Nestec S.A. Biomarkers for predicting degree of weight loss
JP6659830B2 (en) * 2016-04-15 2020-03-04 オムロン株式会社 Biological information analyzer, system, and program
CN105907857A (en) * 2016-04-29 2016-08-31 天津脉络生物科技有限公司 Molecular marker for artery thrombosis, reagent and application thereof
WO2017214684A1 (en) * 2016-06-17 2017-12-21 Adelaide Research & Innovation Pty Ltd Methods and products for identifying conditions associated with cardiac fibrotic remodelling
ES2817087T3 (en) * 2016-08-04 2021-04-06 Hoffmann La Roche Circulating ESM-1 (endocan) in the evaluation of atrial fibrillation
US11079394B2 (en) * 2017-07-25 2021-08-03 Vanderbilt University Detection of angiopoietin-2 and thrombospondin-2 in connection with diagnosing acute heart failure
EP3724662B1 (en) 2017-12-13 2024-02-28 Roche Diagnostics GmbH Circulating angiopoietin-2 (ang-2) and insulin-like growth factor-binding protein 7 (igfbp7) for the prediction of stroke
RU2685859C1 (en) * 2018-07-04 2019-04-23 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Method for prediction of risk of developing ischemic stroke
CN109192250B (en) * 2018-08-01 2021-12-07 华东理工大学 Accelerated simulation method for overcoming rapid migration of surface species in heterogeneous catalysis
WO2020037244A1 (en) * 2018-08-17 2020-02-20 Henry M. Jackson Foundation For The Advancement Of Military Medicine Use of machine learning models for prediction of clinical outcomes
KR20210047304A (en) * 2018-08-22 2021-04-29 에프. 호프만-라 로슈 아게 Cyclic SPON-1 (spondin-1) in atrial fibrillation assessment
US20220187312A1 (en) * 2018-10-31 2022-06-16 Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) Biomarkers of subclinical atherosclerosis
KR102125053B1 (en) * 2018-12-14 2020-06-19 가톨릭대학교 산학협력단 Composition for detecting cardiovascular disease, and kit comprising the same
WO2020168118A1 (en) 2019-02-14 2020-08-20 Mirvie, Inc. Methods and systems for determining a pregnancy-related state of a subject
US11030743B2 (en) * 2019-05-16 2021-06-08 Tencent America LLC System and method for coronary calcium deposits detection and labeling
US10902955B1 (en) * 2020-05-01 2021-01-26 Georgetown University Detecting COVID-19 using surrogates
AU2021364805A1 (en) * 2020-10-20 2023-05-18 Somalogic Operating Co., Inc. Cardiovascular event risk prediction
RU2750716C1 (en) * 2020-11-23 2021-07-01 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр кардиологии" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ кардиологии" Минздрава России) Method for predicting cardiovascular complications in patients with low or moderate cardiovascular risk by assessing their psychological status
WO2022165393A1 (en) * 2021-02-01 2022-08-04 Medtronic, Inc. A method to identify lvad patients with elevated levels of blood activation using coupon tests
RU2757752C1 (en) * 2021-04-26 2021-10-21 Общество с ограниченной ответственностью "Медицинская Технологическая Компания" (ООО МТК) Method for determining individual profile of total cardiovascular risk factors in patient of working age
WO2023023748A1 (en) * 2021-08-26 2023-03-02 3P Healthcare Pty Ltd System and method for cardiovascular health assessment and risk management
EP4230233A1 (en) * 2022-02-22 2023-08-23 mimiX Biotherapeutics Sàrl Method for producing tissue constructs
WO2023201054A1 (en) * 2022-04-15 2023-10-19 Memorial Sloan-Kettering Cancer Center Multi-modal machine learning to determine risk stratification

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5660985A (en) * 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
EP1472352A4 (en) * 2000-03-06 2005-10-12 Smithkline Beecham Corp Novel compounds
US20030224501A1 (en) * 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
HUE039881T2 (en) * 2002-05-09 2019-02-28 Brigham & Womens Hospital Inc 1l1rl-1 as a cardiovascular disease marker
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20050181451A1 (en) * 2004-02-12 2005-08-18 Bates Harold M. Detection of asymptomatic coronary artery disease using atherogenic proteins and acute phase reactants
WO2006063213A2 (en) * 2004-12-10 2006-06-15 University Of Maryland, Baltimore Serum amyloid a protein in inflammation and obesity
CN2783324Y (en) * 2005-04-28 2006-05-24 穆海东 Chip reagent box for cardiovascular diseases diagnosis and predicating multiple indes protein
WO2006135886A2 (en) * 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099239A1 (en) * 2005-06-24 2007-05-03 Raymond Tabibiazar Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
ES2373989T3 (en) * 2006-01-31 2012-02-10 Mitsubishi Chemical Medience Corporation PROCEDURE FOR THE DETERMINATION OF THE STATE OF A DISSEMINATED INTRAVASCULAR COAGULATION SYNDROME.
WO2007146229A2 (en) * 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
EP1887361A1 (en) * 2006-08-07 2008-02-13 Bio-Rad Pasteur Method for the prediction of vascular events
US7947447B2 (en) * 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
RU2376372C2 (en) * 2007-04-03 2009-12-20 Государственное учреждение Научно-исследовательский институт медицинской генетики Томского научного центра Сибирского отделения Российской академии медицинских наук Method for genetic diagnostics of susceptibility to cardiovascular diseases
EP2019318A1 (en) * 2007-07-27 2009-01-28 Erasmus University Medical Center Rotterdam Protein markers for cardiovascular events
US8461303B2 (en) * 2007-08-02 2013-06-11 Gilead Biologics, Inc. LOX and LOXL2 inhibitors and uses thereof
GB0717637D0 (en) * 2007-09-10 2007-10-17 Univ Leiden Future cardiac event biomarkers
WO2009075566A1 (en) * 2007-12-12 2009-06-18 Erasmus University Medical Center Rotterdam Biomarkers for cardiovascular disease
WO2009091581A2 (en) * 2008-01-18 2009-07-23 Vatrix Medical, Inc. Diagnostic biomarkers for vascular aneurysm
US8030097B2 (en) * 2008-04-30 2011-10-04 Versitech Limited and R & C Biogenius Limited Lipocalin-2 as a prognostic and diagnostic marker for heart and stroke risks
WO2010019574A1 (en) * 2008-08-11 2010-02-18 The Board Of Regents Of The University Of Texas System A micro-rna that promotes vascular integrity and uses thereof
CN107085114B (en) * 2008-10-07 2021-05-25 B.R.A.H.M.S有限公司 Biomarkers for predicting primary adverse events
AU2010259022B2 (en) * 2009-06-08 2016-05-12 Singulex, Inc. Highly sensitive biomarker panels
ES2623633T3 (en) * 2009-06-09 2017-07-11 Gendiag.Exe, S.L. Risk markers for cardiovascular disease
EA201270020A1 (en) * 2009-06-15 2012-07-30 Кардиодкс, Инк. DETERMINATION OF THE RISK OF DEVELOPMENT OF ATHEROSCLEROTIC HEART DISEASE
EP2494364A1 (en) * 2009-10-29 2012-09-05 Tethys Bioscience, Inc. Protein and lipid biomarkers providing consistent improvement to the prediction of type 2 diabetes
EP2510116A2 (en) * 2009-12-09 2012-10-17 Aviir, Inc. Biomarker assay for diagnosis and classification of cardiovascular disease
US20120322862A1 (en) * 2010-03-03 2012-12-20 Somalogic, Inc. Aptamers to 4-1BB and Their Use in Treating Diseases and Disorders
SG10201607331WA (en) * 2011-09-30 2016-11-29 Somalogic Inc Cardiovascular risk event prediction and uses thereof
EP2828289B1 (en) * 2012-03-19 2020-02-26 The Brigham and Women's Hospital, Inc. Growth differentiation factor (gdf) 11 for treatment of age-related cardiovascular condition

Also Published As

Publication number Publication date
JP2020024216A (en) 2020-02-13
BR122019023720B1 (en) 2023-01-24
WO2013049674A1 (en) 2013-04-04
CN107422126A (en) 2017-12-01
BR122019023720A2 (en) 2017-04-04
SG10201607331WA (en) 2016-11-29
SG10201906900QA (en) 2019-09-27
BR112014007214A8 (en) 2022-07-26
NZ622118A (en) 2016-01-29
AU2013202112A1 (en) 2013-05-02
EP2761289A4 (en) 2015-08-12
EP2761289A1 (en) 2014-08-06
BR112014007214B1 (en) 2022-08-16
CA3074279A1 (en) 2013-04-04
JP6546318B2 (en) 2019-07-17
KR102248900B1 (en) 2021-05-07
IL231387A (en) 2017-12-31
JP6652781B2 (en) 2020-02-26
JP2014528576A (en) 2014-10-27
RU2651708C2 (en) 2018-04-23
CA2847903A1 (en) 2013-04-04
CN107422126B (en) 2020-03-27
JP6917432B2 (en) 2021-08-11
CN103959060B (en) 2017-05-17
EP2761289B1 (en) 2020-02-12
CN107102151A (en) 2017-08-29
HK1247666A1 (en) 2018-09-28
BR112014007214A2 (en) 2017-04-04
BR122019023720A8 (en) 2022-07-26
KR20200055804A (en) 2020-05-21
KR20140084106A (en) 2014-07-04
CN103959060A (en) 2014-07-30
CA3074279C (en) 2021-10-19
MX2014003153A (en) 2014-04-30
CN114518458A (en) 2022-05-20
AU2013202112B2 (en) 2015-09-24
AU2013202112B9 (en) 2015-10-22
US20130085079A1 (en) 2013-04-04
SG11201400904SA (en) 2014-04-28
CA2847903C (en) 2020-10-27
ES2777002T3 (en) 2020-08-03
IL231387A0 (en) 2014-04-30
JP2018159713A (en) 2018-10-11
MX2020004617A (en) 2020-08-06
ZA201401778B (en) 2018-08-25
RU2014110508A (en) 2015-11-10
US20200166523A1 (en) 2020-05-28
KR102111624B1 (en) 2020-05-18
US20150168423A1 (en) 2015-06-18

Similar Documents

Publication Publication Date Title
IN2014CN01970A (en)
MX2013001042A (en) Pancreatic cancer biomarkers and uses thereof.
IN2014CN01787A (en)
EA030186B9 (en) Method for performing quantitation assays
MY170164A (en) Aptamer-based multiplexed assays
WO2013052505A3 (en) Methods and devices for assessing risk to a putative offspring of developing a condition
WO2013075055A3 (en) Kits and methods for assessing appendicitis
WO2014186761A3 (en) Methods for determining responsiveness to an anti-cd47 agent
EP3029153A3 (en) Mesothelioma biomarkers and uses thereof
WO2012177945A3 (en) Diagnostic methods for eosinophilic esophagitis
WO2012019193A3 (en) Assay systems for genetic analysis
GB2515983A (en) Methods and compositions for providing a preeclampsia assessment
MX363201B (en) Method, array and use for determining the presence of pancreatic cancer.
MX2016006125A (en) Method, array and use thereof for determining pancreatic cancer.
WO2013188686A3 (en) Biomarker test for prediction or early detection of preeclampsia and/or hellp syndrome
GB201207297D0 (en) Analytical methods and arrays for use in the same
GB201014837D0 (en) Biomarker signatures and uses thereof
MX2015001961A (en) Assay methods and systems.
WO2011137388A3 (en) Identification and use of biomarkers for detection and quantification of the level of radiation exposure in a biological sample
WO2013112836A3 (en) Diagnostic and prognostic biomarkers for cancer
IN2015DN01501A (en)
WO2015189591A3 (en) Method and arrays for use in diagnosing early breast cancer
MX2015004419A (en) Detecting an analyte and determining the concentration of an analyte using magnetizable beads.
EP3557259A3 (en) Methods and arrays for use in the same
WO2013028544A3 (en) Compositions and methods for detecting and discriminating between yeast or mold